Demiray, M. Et Al. 2006. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: A prospective pilot study. CANCER INVESTIGATION , vol.24, no.7 , 669-676.

Demiray, M., Ulukaya, E., Arslan, M., Gokgoz, S., Saraydaroglu, O., Ercan, İ., ... Evrensel, T.(2006). Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: A prospective pilot study. CANCER INVESTIGATION , vol.24, no.7, 669-676.

Demiray, Mutlu Et Al. "Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: A prospective pilot study," CANCER INVESTIGATION , vol.24, no.7, 669-676, 2006

Demiray, Mutlu Et Al. "Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: A prospective pilot study." CANCER INVESTIGATION , vol.24, no.7, pp.669-676, 2006

Demiray, M. Et Al. (2006) . "Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: A prospective pilot study." CANCER INVESTIGATION , vol.24, no.7, pp.669-676.

@article{article, author={Mutlu Demiray Et Al. }, title={Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: A prospective pilot study}, journal={CANCER INVESTIGATION}, year=2006, pages={669-676} }